Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX EPS (Diluted)

Discontinued — last reported Q1 '26

EPS (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
$8.26+170%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$1.82+49.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$0.25+56.3%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$0.71+13.4%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$0.09+55.0%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.56B-45.9%
Enterprise value$1.36B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's EPS (diluted)?
MoonLake Immunotherapeutics (MLTX) reported EPS (diluted) of -$0.98 in Q1 2026.
How has MoonLake Immunotherapeutics's EPS (diluted) changed year-over-year?
MoonLake Immunotherapeutics's EPS (diluted) decreased by 55.6% year-over-year, from -$0.63 to -$0.98.
What is the long-term trend for MoonLake Immunotherapeutics's EPS (diluted)?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's EPS (diluted) has grown at a -27.0% compound annual growth rate (CAGR), from -$12.37 to -$3.52.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.